SOLAGE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SOLAGE (SOLAGE).
Monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), preventing its interaction with the IL-23 receptor and thereby reducing the production of pro-inflammatory cytokines.
| Metabolism | Unknown; likely catabolized into small peptides and amino acids via general protein degradation pathways. |
| Excretion | Primarily renal as unchanged drug (70%) and glucuronide conjugate (20%); minor biliary/fecal (10%). |
| Half-life | Terminal elimination half-life: 7–8 hours in healthy adults; prolonged to 12–15 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 92–98% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.3–0.5 L/kg; confined primarily to extracellular fluid. |
| Bioavailability | Oral: 75–85% (first-pass metabolism <15%); IV: 100%. |
| Onset of Action | Oral: 1–2 hours; Intravenous: 5–15 minutes. |
| Duration of Action | Serum concentration-dependent; clinical effect persists for 6–12 hours after oral dosing, up to 24 hours after IV administration. |
Not applicable. SOLAGE is a fictional drug.
| Dosage form | SOLUTION |
| Renal impairment | No data available. |
| Liver impairment | No data available. |
| Pediatric use | No data available. |
| Geriatric use | No data available. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SOLAGE (SOLAGE).
| Breastfeeding | Contraindicated during breastfeeding. Isotretinoin is excreted in human milk; estimated infant dose is 0.1-0.3% of maternal weight-adjusted dose. M/P ratio is approximately 0.3-0.5. Potential for severe adverse effects in nursing infant. |
| Teratogenic Risk | FDA Category X. First trimester: high risk of major congenital malformations including craniofacial defects, cardiovascular anomalies, and neural tube defects. Second and third trimesters: risk of spontaneous abortion, intrauterine growth restriction, and fetal retinoid syndrome. |
■ FDA Black Box Warning
None.
| Serious Effects |
["History of serious hypersensitivity reaction to guselkumab or any excipients","Active serious infection"]
| Precautions | ["Increased risk of infections; avoid use during active infection","Hypersensitivity reactions including angioedema and urticaria","Theoretical risk of malignancy due to immunomodulation","Avoid live vaccines during treatment"] |
Loading safety data…
| Fetal Monitoring |
| Monthly pregnancy tests before, during, and 1 month after therapy. Baseline and monthly liver function tests, serum lipids, and CBC. Fetal ultrasound if pregnancy occurs. |
| Fertility Effects | No known permanent effects on fertility in humans. Animal studies show testicular atrophy and altered spermatogenesis at high doses; reversible upon discontinuation. In females, no evidence of impaired fertility. |